Acrivon Therapeutics, Inc. (ACRV) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 19, 2026, by Acrivon Therapeutics, Inc., a Delaware corporation. The filing primarily serves to announce financial results for the fourth quarter and full year ended December 31, 2025, and to provide updates on the company's clinical pipeline under Regulation FD.
Key Financial Metrics
The filing text references a press release (Exhibit 99.1) containing the specific financial results for the fourth quarter and full year ended December 31, 2025. However, the body of this 8-K does not explicitly state numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for these metrics.
Material Changes and Clinical Updates
Significant operational updates were disclosed regarding the registrational intent ACR-368 phase 2b study:
- Initiation of Arm 4: The company initiated Arm 4 to study ACR-368 monotherapy in subjects with serous type endometrial cancer who have had two or fewer prior lines of therapy. This decision was based on promising clinical data and observed OncoSignature biomarker (BM) upregulation.
- Completion of Arm 2: The company completed exploratory Arm 2, which treated biomarker-negative (BM-) subjects with three or fewer prior lines of therapy using ACR-368 combined with ultra-low dose gemcitabine (ULDG) sensitization.
- Arm 2 Outcomes: Objectives for Arm 2 were achieved, supporting the hypothesis that ULDG may contribute to ACR-368 efficacy in BM- subjects while maintaining a favorable tolerability profile.
Guidance, Outlook, and Risks
The filing incorporates a Corporate Presentation (Exhibit 99.2) that updates the business plan and pipeline status. The initiation of Arm 4 indicates a strategic focus on expanding the patient population for ACR-368 based on biomarker data. The filing includes standard disclaimers stating that the information in Items 2.02 and 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2025 financial figures, including cash position and burn rate.
- Examine Exhibit 99.2 (Corporate Presentation) for detailed timelines regarding the ACR-368 phase 2b study and future milestones.
- Verify the specific criteria for "OncoSignature biomarker upregulation" and its correlation with clinical outcomes in the full press release.
- Confirm the regulatory status and enrollment targets for the newly initiated Arm 4 of the phase 2b study.